Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting KRASG12C in colorectal cancer: the beginning of a new era
Davide Ciardiello, Brigida Anna Maiorano, Erika Martinelli
ESMO Open (2022) Vol. 8, Iss. 1, pp. 100745-100745
Open Access | Times Cited: 24

Showing 24 citing articles:

Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials
Julien Taı̈eb, Frank A. Sinicrope, Levi D. Pederson, et al.
Annals of Oncology (2023) Vol. 34, Iss. 11, pp. 1025-1034
Open Access | Times Cited: 27
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
Javier Ros, Caterina Vaghi, Iosune Baraibar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3304-3304
Open Access | Times Cited: 14
Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors
Marcell Baranyi, Eszter Molnár, Luca Hegedűs, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 6, pp. 1059-1072
Open Access | Times Cited: 12
Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis
Qian Chen, Weihao Lin, Xiao-xiang Zhou, et al.
Pharmacological Research (2024) Vol. 200, pp. 107060-107060
Open Access | Times Cited: 9
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review
Davide Ciardiello, Gianluca Mauri, Andrea Sartore‐Bianchi, et al.
Cancer Treatment Reviews (2024) Vol. 124, pp. 102683-102683
Closed Access | Times Cited: 8
KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics
Ioannis A. Voutsadakis
Critical Reviews in Oncology/Hematology (2023) Vol. 186, pp. 103987-103987
Closed Access | Times Cited: 15
A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor
Yan Lv, Zixuan Yang, Yiming Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2487-2511
Closed Access | Times Cited: 5
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Wei Ye, Lu Xin, Yue Qiao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189108-189108
Closed Access | Times Cited: 5
Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance
Samuele Tardito, Serena Matis, Maria Raffaella Zocchi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7131-7131
Open Access | Times Cited: 4
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response
Peiyuan Yang, Yongchao Li
Investigational New Drugs (2025)
Closed Access
The emerging role of Sotorasib plus Panitumumab combination therapy in colorectal cancer treatment
Emmanuel Kokori, Gbolahan Olatunji, Ikponmwosa Jude Ogieuhi, et al.
International Journal of Clinical Oncology (2025)
Closed Access
Treatment of extended RAS/ BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations
Ioannis A. Voutsadakis
Pharmacogenomics (2025), pp. 1-14
Closed Access
Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer
Yoshihito Kano, Mitsukuni Suenaga, Hiroyuki Uetake
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6546-6558
Open Access | Times Cited: 9
DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations
Federico Innocenti, Wancen Mu, Xueping Qu, et al.
Journal of Clinical Oncology (2023) Vol. 42, Iss. 4, pp. 399-409
Closed Access | Times Cited: 7
Recent Perspectives on Cardiovascular Toxicity Associated with Colorectal Cancer Drug Therapy
Monu Kumar Kashyap, Shubhada Mangrulkar, Sapana Kushwaha, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 10, pp. 1441-1441
Open Access | Times Cited: 6
The effects of KRAS Mutations on the Prognosis of Rectal Cancer Following Neoadjuvant Chemoradiotherapy and Surgery
Ji Sun Park, Soon Seong Lee, Youn Seon Choi
Asian Pacific Journal of Cancer Prevention (2024) Vol. 25, Iss. 7, pp. 2337-2342
Open Access | Times Cited: 1
Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors
Sara Cherri, Laura Melocchi, Laura Gandolfi, et al.
Life (2023) Vol. 13, Iss. 2, pp. 395-395
Open Access | Times Cited: 3
Riok1, A Novel Potential Target in MSI-High p53 Mutant Colorectal Cancer Cells
Sharon Shechter, Sapir Ya’ar Bar, Hamdan Khattib, et al.
Molecules (2023) Vol. 28, Iss. 11, pp. 4452-4452
Open Access | Times Cited: 2
Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study
Seiichiro Mitani, Yosuke Kito, Kaori Hino, et al.
Targeted Oncology (2023) Vol. 18, Iss. 5, pp. 707-715
Closed Access | Times Cited: 2
Identification and validation of a novel prognosis model based on m5C-related long non-coding RNAs in colorectal cancer
Ziyang Di, Gaoran Xu, Zheyu Ding, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Is the transverse colon the new right?—similarities in EGFR drug response and prognosis
Soledad Cameselle‐García, Ana Fernández Montés
Journal of Gastrointestinal Oncology (2024) Vol. 15, Iss. 5, pp. 2363-2366
Open Access
Annona muricata ethanolic extract protects BALB/c mice against colitis-associated colon cancer through modulation of cytokine levels and KRAS and APC expression
María del Rosario Huizar-López, Anne Santerre, Jaime Coronilla-Martínez, et al.
Advances in Traditional Medicine (2024)
Closed Access
Investigating the pathogenicity of uncommon KRAS mutations and their association with clinicopathological characteristics in patients with colorectal cancer
Riccardo Adorisio, Davide Ciardiello, Alessandra Rappa, et al.
Journal of Molecular Diagnostics (2024)
Closed Access
8-Aza Quinazolines as Brain Penetrant SOS1 Inhibitors for Treating Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 11, pp. 1487-1488
Closed Access
Page 1

Scroll to top